GeneDx (NASDAQ:WGS) Shares Down 12.2% After Insider Selling

GeneDx Holdings Corp. (NASDAQ:WGS)’s stock price traded down 12.2% during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $82.09 and last traded at $83.6350. 993,648 shares were traded during trading, an increase of 37% from the average session volume of 724,660 shares. The stock had previously closed at $95.23.

Specifically, COO Bryan Dechairo sold 3,413 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $99.53, for a total value of $339,695.89. Following the completion of the transaction, the chief operating officer directly owned 5,961 shares of the company’s stock, valued at $593,298.33. The trade was a 36.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Katherine Stueland sold 1,653 shares of GeneDx stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $94.00, for a total value of $155,382.00. Following the sale, the chief executive officer owned 16,458 shares of the company’s stock, valued at approximately $1,547,052. This represents a 9.13% decrease in their position. The SEC filing for this sale provides additional information. In related news, CFO Kevin Feeley sold 317 shares of the business’s stock in a transaction dated Thursday, January 29th. The shares were sold at an average price of $93.99, for a total value of $29,794.83. Following the completion of the transaction, the chief financial officer owned 9,168 shares of the company’s stock, valued at approximately $861,700.32. The trade was a 3.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on WGS shares. BTIG Research lifted their price target on shares of GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Wall Street Zen upgraded shares of GeneDx from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. Guggenheim reiterated a “buy” rating and issued a $170.00 price target (up from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Wells Fargo & Company set a $155.00 price target on GeneDx and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Finally, Canaccord Genuity Group lifted their price objective on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, GeneDx currently has an average rating of “Moderate Buy” and a consensus target price of $138.13.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Analyst sentiment remains constructive — several firms maintain Buy/Upgraded ratings and the consensus is a “Moderate Buy,” which supports medium‑term upside. Analyst Consensus
• Neutral Sentiment: Company scheduled to report Q4 2025 results on Feb 23, 2026 — a clear near‑term catalyst that can either amplify a rebound or deepen the decline depending on results and guidance. Q4 2025 Release Date
• Negative Sentiment: Clustered insider selling by senior executives: COO Bryan Dechairo sold 3,413 shares (~$339.7k) and CEO Katherine Stueland sold 1,653 shares; the CFO also sold 317 shares — these C‑suite sales can signal reduced near‑term insider conviction and weigh on investor sentiment. COO Sale CEO Sale CFO Sale
• Negative Sentiment: Technical and flow factors look unfavorable: shares are trading well below recent 50‑day and 200‑day averages and turnover is elevated versus normal volume — these conditions often trigger momentum selling and increase volatility. Price & Technicals

GeneDx Stock Performance

The stock has a market cap of $2.47 billion, a PE ratio of 948.33 and a beta of 2.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. The stock has a 50-day simple moving average of $129.42 and a 200-day simple moving average of $124.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada increased its position in shares of GeneDx by 30.2% in the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock worth $2,611,000 after acquiring an additional 6,840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in GeneDx by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after purchasing an additional 453 shares during the period. NewEdge Advisors LLC increased its holdings in GeneDx by 270,700.0% in the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after purchasing an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in GeneDx by 67.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after purchasing an additional 11,375 shares during the period. Finally, Aberdeen Group plc acquired a new position in shares of GeneDx during the second quarter worth about $12,622,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.